Analysts See $-0.38 EPS for Verastem, Inc. (VSTM)

March 21, 2018 - By Linda Rogers

 Analysts See $ 0.38 EPS for Verastem, Inc. (VSTM)
Investors sentiment increased to 1.4 in 2017 Q3. Its up 0.23, from 1.17 in 2017Q2. It increased, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported.
Morgan Stanley reported 5,538 shares or 0% of all its holdings. Moreover, Tower Cap Ltd (Trc) has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 579 shares. 27,511 are owned by Stoneridge Invest Prns Lc. Moreover, Advisory Services Network Limited Company has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM) for 15,325 shares. Jacobs Levy Equity Management reported 160,390 shares. Cubist Systematic Strategies reported 0.01% in Verastem, Inc. (NASDAQ:VSTM). Deutsche Natl Bank Ag invested in 0% or 224,591 shares. Barclays Public Ltd Co holds 900 shares or 0% of its portfolio. Wells Fargo & Mn has 19,951 shares. Raymond James Financial Advsr reported 0% stake. Goldman Sachs Group holds 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 14,965 shares. Invesco stated it has 0% in Verastem, Inc. (NASDAQ:VSTM). Rbf Capital Limited Company accumulated 0.01% or 11,580 shares. Beaumont Prtn Ltd reported 10,000 shares or 0.01% of all its holdings. Susquehanna International Group Inc Ltd Liability Partnership invested in 0% or 75,526 shares.

Analysts expect Verastem, Inc. (NASDAQ:VSTM) to report $-0.38 EPS on March, 22.They anticipate $0.06 EPS change or 18.75 % from last quarter’s $-0.32 EPS. After having $-0.61 EPS previously, Verastem, Inc.’s analysts see -37.70 % EPS growth. The stock decreased 1.27% or $0.04 during the last trading session, reaching $3.11. About 533,254 shares traded. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since March 21, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 11 analysts covering Verastem (NASDAQ:VSTM), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Verastem had 31 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Neutral” rating given on Tuesday, September 29 by UBS. The rating was maintained by H.C. Wainwright on Wednesday, December 13 with “Buy”. Oppenheimer maintained the shares of VSTM in report on Monday, June 26 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, September 25 report. On Monday, September 28 the stock rating was downgraded by Roth Capital to “Neutral”. The company was downgraded on Tuesday, September 29 by JMP Securities. As per Wednesday, September 6, the company rating was upgraded by Cantor Fitzgerald. TH Capital downgraded the stock to “Neutral” rating in Monday, September 28 report. The firm has “Buy” rating given on Tuesday, July 25 by Oppenheimer. The company was maintained on Thursday, March 15 by H.C. Wainwright.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $157.99 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More important recent Verastem, Inc. (NASDAQ:VSTM) news were published by: which released: “Verastem to Present at the 30” on February 26, 2018, also published article titled: “Verastem In CLL: Opportunity And Caution”, published: “Verastem to Present at Upcoming Conferences” on March 14, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) was released by: and their article: “Verastem Reports Year-End 2017 Financial Results” with publication date: March 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.